Literature DB >> 22221288

Type II focal cortical dysplasia: electroclinical phenotype and surgical outcome related to imaging.

Francine Chassoux1, Elisabeth Landré, Charles Mellerio, Baris Turak, Michael W Mann, Catherine Daumas-Duport, Catherine Chiron, Bertrand Devaux.   

Abstract

PURPOSE: Type II focal cortical dysplasia (TTFCD), a highly epileptogenic lesion with severe epilepsy curable by surgery, is missed by magnetic resonance imaging (MRI) in about one third of cases. Little is known about the electroclinical presentation in these MRI-negative patients and a poor surgical outcome is frequently reported. We compared the clinical and neurophysiologic features in MRI-negative and MRI-positive cases in order to better identify candidates for surgery.
METHODS: Among 62 consecutive TTFCD patients (38 male, 24 female; 7-52 years old; 22 children) operated for intractable epilepsy, 25 (40%) presented negative MRI findings. We compared the history of epilepsy; the type, frequency, and distribution of seizures; neurologic examination cognitive and psychiatric impairment; interictal-ictal electroencephalography (EEG) and stereo-EEG (SEEG) data, fluorodeoxyglucose positron emission tomography (FDG-PET) data, neuropathologic findings; and surgical outcome in the MRI-negative and the MRI-positive groups. KEY
FINDINGS: Severe partial epilepsy beginning in childhood, high seizure frequency including status epilepticus, stereotyped seizures suggestive of precise brain localization, extratemporal location and functional area involvement were characteristic and similarly found in both groups. On EEG, pseudorhythmic activity was found in about 40% of patients in each group. SEEG recordings demonstrated the typical pattern characterizing TTFCD in both groups. FDG-PET had a localization value in 84% of the MRI-negative cases and helped to delineate the dysplastic cortex in 65% of the MRI-positive cases. The combination of imaging and neurophysiologic data allowed us to perform safe and restricted resections, limited to a single gyrus in more than half of all cases. In addition, we were able to avoid invasive monitoring in most MRI-positive cases and even in some selected MRI-negative cases. The proportion of patients with a favorable surgical outcome was comparable in both groups (88% in MRI-negative and 94% in MRI-positive cases). The main difference between the groups was a significantly higher frequency of sleep-related epilepsy in the MRI-negative group (p = 0.028). This phenotypic characteristic provides a new argument for TTFCD in MRI-negative extratemporal epilepsy. SIGNIFICANCE: These results lead us to consider that children or adult patients in whom electroclinical data suggest TTFCD, are highly suitable for surgery, especially for cryptogenic sleep-related epilepsy. Wiley Periodicals, Inc.
© 2012 International League Against Epilepsy.

Entities:  

Mesh:

Year:  2012        PMID: 22221288     DOI: 10.1111/j.1528-1167.2011.03363.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  31 in total

1.  Bottom-of-Sulcus Dysplasia as an Epileptic Syndrome: The Power of Clinical Correlation.

Authors:  Barbara C Jobst
Journal:  Epilepsy Curr       Date:  2015 Nov-Dec       Impact factor: 7.500

Review 2.  Nocturnal frontal lobe epilepsy.

Authors:  Lino Nobili; Paola Proserpio; Romina Combi; Federica Provini; Giuseppe Plazzi; Francesca Bisulli; Laura Tassi; Paolo Tinuper
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

Review 3.  Electro-clinical-pathological correlations in focal cortical dysplasia (FCD) at young ages.

Authors:  Hans Holthausen; Tom Pieper; Peter Winkler; Ingmar Bluemcke; Manfred Kudernatsch
Journal:  Childs Nerv Syst       Date:  2014-09-27       Impact factor: 1.475

Review 4.  Basic mechanisms of epileptogenesis in pediatric cortical dysplasia.

Authors:  Sara Abdijadid; Gary W Mathern; Michael S Levine; Carlos Cepeda
Journal:  CNS Neurosci Ther       Date:  2014-11-18       Impact factor: 5.243

5.  18F-FDG PET in drug-resistant epilepsy due to focal cortical dysplasia type 2: additional value of electroclinical data and coregistration with MRI.

Authors:  Serge Desarnaud; Charles Mellerio; Franck Semah; Agathe Laurent; Elisabeth Landre; Bertrand Devaux; Catherine Chiron; Vincent Lebon; Francine Chassoux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-29       Impact factor: 9.236

6.  Type II focal cortical dysplasia: electroclinical study and surgical outcome in 31 pediatric patients.

Authors:  Daniel Noli; Marcelo Bartuluchi; Federico Sanchez González; María Carolina Kaltenmeier; Ricardo Cersosimo; Carlos Rugilo; Juan P Princich; Fabiana Lubieniecki; Hugo Pomata; Roberto Caraballo
Journal:  Childs Nerv Syst       Date:  2013-07-07       Impact factor: 1.475

7.  Outcome of surgery in children with focal cortical dysplasia younger than 5 years explored by stereo-electroencephalography.

Authors:  G Dorfmüller; S Ferrand-Sorbets; M Fohlen; C Bulteau; F Archambaud; O Delalande; M Chipaux; D Taussig
Journal:  Childs Nerv Syst       Date:  2014-10-09       Impact factor: 1.475

Review 8.  Outcome after epilepsy surgery for cortical dysplasia in children.

Authors:  Ahsan N V Moosa; Ajay Gupta
Journal:  Childs Nerv Syst       Date:  2014-11       Impact factor: 1.475

9.  Understanding Lennox-Gastaut syndrome: insights from focal epilepsy patients with Lennox-Gastaut features.

Authors:  Sophie Dupont; Raluca Banica-Wolters; Isabelle An-Gourfinkel; Virginie Lambrecq; Vincent Navarro; Claude Adam; Vi-Huong Nguyen-Michel
Journal:  J Neurol       Date:  2017-06-05       Impact factor: 4.849

10.  Can histologically normal epileptogenic zone share common electrophysiological phenotypes with focal cortical dysplasia? SEEG-based study in MRI-negative epileptic patients.

Authors:  Stanislas Lagarde; Julia Scholly; Irina Popa; Maria Paola Valenti-Hirsch; Agnès Trebuchon; Aileen McGonigal; Mathieu Milh; Anke M Staack; Béatrice Lannes; Benoît Lhermitte; François Proust; Mustapha Benmekhbi; Didier Scavarda; Romain Carron; Dominique Figarella-Branger; Edouard Hirsch; Fabrice Bartolomei
Journal:  J Neurol       Date:  2019-05-04       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.